Authors:
UNDERHILL C
CLARKE K
GREEN M
MITCHELL P
BARTLETT J
BASSER R
MAHER D
CEBON J
FINDLAY M
DALLEY D
BYRNE M
CHER L
GELDARD H
SHIMOSAKA A
BURGESS A
KAYE A
Citation: C. Underhill et al., MX2 (KRN8602), AN ACTIVE NEW AGENT WITH LOW TOXICITY IN HIGH-GRADE MALIGNANT GLIOMA, Annals of oncology, 9, 1998, pp. 650-650
Authors:
CLARKE K
BASSER RL
MAHER D
MORGAN DJ
CEBON J
FOX RM
HILL JS
ALT C
BARTLET J
GELDARD H
KAYE AH
GREEN MD
Citation: K. Clarke et al., PHASE-I AND PHARMACOKINETIC STUDY OF KRN8602 ALONE AND WITH FILGRASTIM IN PATIENTS WITH ADVANCED CANCER, Journal of clinical oncology, 16(6), 1998, pp. 2181-2187
Authors:
MORGAN DJ
HILL JS
CLARKE K
STYLLI SS
PARK SJ
CEBON J
BASSER RL
KAYE AH
GELDARD H
MAHER DW
GREEN MD
Citation: Dj. Morgan et al., EFFECT OF FILGRASTIM ON THE PHARMACOKINETICS OF MX2 HYDROCHLORIDE IN PATIENTS WITH ADVANCED MALIGNANT DISEASE, Cancer chemotherapy and pharmacology, 41(5), 1998, pp. 423-426
Authors:
MORGAN DJ
HILL JS
CLARKE K
STYLLI SS
PARK SJ
CEBON J
BASSER RL
KAYE AH
GELDARD H
MAHER DW
GREEN MD
Citation: Dj. Morgan et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF MX2 HYDROCHLORIDE IN PATIENTS WITH ADVANCED MALIGNANT DISEASE, Cancer chemotherapy and pharmacology, 40(3), 1997, pp. 202-208